[go: up one dir, main page]

UY36550A - Oligómeros antisentido de tau y sus usos - Google Patents

Oligómeros antisentido de tau y sus usos

Info

Publication number
UY36550A
UY36550A UY0001036550A UY36550A UY36550A UY 36550 A UY36550 A UY 36550A UY 0001036550 A UY0001036550 A UY 0001036550A UY 36550 A UY36550 A UY 36550A UY 36550 A UY36550 A UY 36550A
Authority
UY
Uruguay
Prior art keywords
tau
oligómeros
antisentido
tau protein
expression
Prior art date
Application number
UY0001036550A
Other languages
English (en)
Inventor
Richard E Olson
Angela M Cacace
Hagedorn Peter
Anja Mølhart Høg
Marianne Lerbeck Jensen
Niels Fisker Nielsen
Li Dong
Jeffrey M Brown
Stephen E Mercer
Original Assignee
Roche Innovation Ct Copenhagen As
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Innovation Ct Copenhagen As, Bristol Myers Squibb Company Una Corporación Del Estado De Delaware filed Critical Roche Innovation Ct Copenhagen As
Publication of UY36550A publication Critical patent/UY36550A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a compuestos oligoméricos (oligómeros), que se dirigen a mARN de Tau en una célula, lo cual produce la reducción de la expresión de la proteína Tau. La reducción de la expresión de la proteína Tau es beneficiosa para el tratamiento de determinados trastornos médicos, por ejemplo, un trastorno neurológico.
UY0001036550A 2015-02-04 2016-02-04 Oligómeros antisentido de tau y sus usos UY36550A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562112058P 2015-02-04 2015-02-04
US201562156684P 2015-05-04 2015-05-04
US201562237922P 2015-10-06 2015-10-06
US201562238941P 2015-10-08 2015-10-08
US201662279612P 2016-01-15 2016-01-15
US201662279614P 2016-01-15 2016-01-15
US201662279610P 2016-01-15 2016-01-15

Publications (1)

Publication Number Publication Date
UY36550A true UY36550A (es) 2016-08-31

Family

ID=55443327

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036550A UY36550A (es) 2015-02-04 2016-02-04 Oligómeros antisentido de tau y sus usos

Country Status (24)

Country Link
US (3) US10799523B2 (es)
EP (2) EP3653712B1 (es)
JP (1) JP2018505676A (es)
KR (1) KR20180016970A (es)
CN (1) CN107922946A (es)
AU (1) AU2016215155A1 (es)
BR (1) BR112017016663A2 (es)
CA (1) CA2975525A1 (es)
CL (1) CL2017001956A1 (es)
CO (1) CO2017009008A2 (es)
CR (1) CR20170359A (es)
DK (1) DK3253875T3 (es)
HK (1) HK1248276A1 (es)
IL (1) IL253730A0 (es)
MA (1) MA41586A (es)
MX (1) MX2017010066A (es)
PE (1) PE20171766A1 (es)
PH (1) PH12017550069A1 (es)
RU (1) RU2017127609A (es)
SG (1) SG11201706293XA (es)
TW (1) TW201641691A (es)
UY (1) UY36550A (es)
WO (1) WO2016126995A1 (es)
ZA (1) ZA201705119B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
BR112014001244A2 (pt) 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
AU2013202595B2 (en) 2012-03-30 2016-04-21 Biogen Ma Inc. Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
ES2862073T3 (es) 2012-07-13 2021-10-06 Wave Life Sciences Ltd Grupo auxiliar asimétrico
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
CN115181778A (zh) 2015-02-04 2022-10-14 百时美施贵宝公司 选择治疗性分子的方法
JOP20200228A1 (ar) * 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
AU2017367722B2 (en) * 2016-12-01 2024-02-01 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
AU2018375807B2 (en) * 2017-12-01 2025-04-10 The Texas A&M University System Angelman syndrome antisense treatment
SG11202006528XA (en) * 2018-01-12 2020-08-28 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN120310791A (zh) 2018-01-12 2025-07-15 百时美施贵宝公司 靶向α-突触核蛋白的反义寡核苷酸及其用途
PE20211197A1 (es) 2018-02-09 2021-07-01 Genentech Inc Oligonucleotidos para modular la expresion de tmem106b
AU2019218987B2 (en) 2018-02-12 2025-04-24 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
CN111868068A (zh) 2018-03-13 2020-10-30 詹森药业有限公司 用于在tau蛋白病变治疗中使用的经修饰的寡核苷酸
WO2019200273A1 (en) 2018-04-13 2019-10-17 Bristol-Myers Squibb Company Novel phosphorous (v)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (v) compounds
JP7379387B2 (ja) 2018-06-05 2023-11-14 エフ． ホフマン－ラ ロシュ アーゲー Ａｔｘｎ２発現を制御するためのオリゴヌクレオチド
KR102585973B1 (ko) 2018-07-03 2023-10-10 에프. 호프만-라 로슈 아게 타우 발현을 조절하기 위한 올리고뉴클레오티드
CN113226333A (zh) 2018-10-02 2021-08-06 桑格摩生物治疗股份有限公司 用于调控Tau蛋白的方法和组合物
KR20210149107A (ko) * 2019-04-03 2021-12-08 브리스톨-마이어스 스큅 컴퍼니 Angptl2 안티센스 올리고뉴클레오티드 및 그의 용도
US11286485B2 (en) 2019-04-04 2022-03-29 Hoffmann-La Roche Inc. Oligonucleotides for modulating ATXN2 expression
EP3947677A1 (en) 2019-04-04 2022-02-09 F. Hoffmann-La Roche AG Oligonucleotides for modulating atxn2 expression
JP7155302B2 (ja) 2019-06-06 2022-10-18 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘｎ３を標的とするアンチセンスオリゴヌクレオチド
EP4031119B1 (en) * 2019-09-17 2025-12-17 Harmony Biosciences Management, Inc. Transdermal treatment of behavioral impairment in developmental and epileptic encephalopathy with cbd
BR112022012340A2 (pt) 2020-01-16 2022-09-06 Bristol Myers Squibb Co Reagentes e uso dos mesmos para síntese enantiodivergente modular de ligações c-p
MX2022012293A (es) * 2020-03-30 2022-10-27 Alnylam Pharmaceuticals Inc Composiciones de agentes de acido ribonucleico de interferencia (arni) de la proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
JP2023529457A (ja) 2020-06-09 2023-07-10 ロシュ イノベーション センター コペンハーゲン エーエス 治療用ポリヌクレオチドに使用するためのグアノシン類似体
US20230060373A1 (en) 2020-12-03 2023-03-02 Hoffmann-La Roche Inc. Antisense Oligonucleotides Targeting ATXN3
AR124229A1 (es) 2020-12-03 2023-03-01 Hoffmann La Roche Oligonucleótidos antisentido que actúan sobre atxn3
AR124302A1 (es) * 2020-12-11 2023-03-15 Eisai R&D Man Co Ltd Gápmeros de oligonucleótidos de objetivo tau
US20220259601A1 (en) * 2021-02-17 2022-08-18 Q-State Biosciences, Inc. Ube3a antisense therapeutics
WO2023278436A1 (en) * 2021-06-29 2023-01-05 Shape Therapeutics Inc. Engineered guide rnas and polynucleotides
JP2025517123A (ja) * 2022-05-13 2025-06-03 ユリウス－マクシミリアンズ－ウニヴェルジテート ウュルツブルグ アルツハイマー病の処置のためのＨＮＲＮＰ Ｒ－媒介Ｍａｐｔ ｍＲＮＡ輸送の遮断を介する軸索タウ（ｔａｕ）タンパク質蓄積を減少させるための方法及び分子
KR20250119484A (ko) * 2024-01-30 2025-08-07 소바젠 주식회사 Mtor 활성 또는 발현을 조절하기 위한 화합물 및 이의 용도

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5157021A (en) 1985-03-15 1992-10-20 Novo Nordisk A/S Insulin derivatives and pharmaceutical preparations containing these derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5264423A (en) * 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5248670A (en) * 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5453491A (en) 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
EP0509826A1 (en) 1991-04-19 1992-10-21 Schering Corporation Subunit of the human interleukin 3 receptor
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5227158A (en) 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
DK0848755T4 (da) 1995-09-08 2011-05-23 Genentech Inc VEGF relateret protein
JP2000515735A (ja) 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
US6159462A (en) 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
GB9812127D0 (en) 1998-06-06 1998-08-05 Univ Glasgow Detection of neural activity
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
AU776672B2 (en) 1998-12-30 2004-09-16 Beth Israel Deaconess Medical Center Characterization of a calcium channel family
DK1141014T3 (da) 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
JP2002535967A (ja) 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
DK1521774T3 (da) * 2002-07-12 2008-10-27 Axon Neuroscience Trunkerede Tau-proteiner
DK2284269T3 (en) 2002-11-18 2017-10-23 Roche Innovation Ct Copenhagen As Antisense design
WO2004069992A2 (en) 2003-02-10 2004-08-19 Santaris Pharma A/S Oligomeric compounds for the modulation of ras expression
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
EP1799859B1 (en) 2004-09-17 2014-07-02 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
EP1984381B1 (en) 2006-01-27 2010-09-29 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2007131237A2 (en) 2006-05-05 2007-11-15 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of ptp1b
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
EP2410053B2 (en) * 2006-10-18 2020-07-15 Ionis Pharmaceuticals, Inc. Antisense compounds
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2009090182A1 (en) 2008-01-14 2009-07-23 Santaris Pharma A/S C4'-substituted - dna nucleotide gapmer oligonucleotides
EP2265627A2 (en) 2008-02-07 2010-12-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2009124238A1 (en) 2008-04-04 2009-10-08 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
EP2274423A2 (en) 2008-04-04 2011-01-19 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
CN101812127B (zh) * 2009-02-19 2013-03-06 中国科学技术大学 微管结合蛋白及其编码基因与应用
US20100275274A1 (en) * 2009-04-28 2010-10-28 National Yang-Ming University Mouse model for depression, schizophrenia and alzheimer's disease
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US9364495B2 (en) 2009-10-20 2016-06-14 Roche Innovation Center Copenhagen A/S Oral delivery of therapeutically effective LNA oligonucleotides
WO2011085102A1 (en) 2010-01-11 2011-07-14 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011115818A1 (en) 2010-03-17 2011-09-22 Isis Pharmaceuticals, Inc. 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2796809C (en) 2010-04-21 2019-05-28 Optosecurity Inc. Method and system for use in performing security screening
WO2012109395A1 (en) 2011-02-08 2012-08-16 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US8778884B2 (en) 2011-05-26 2014-07-15 Fondazione Salvatore Maugeri Clinica del Lavora e Della Riabilitazione Glioprotectant peptide for use in the treatment of amyotrophic lateral sclerosis (ALS) and methods related thereto
US9243291B1 (en) 2011-12-01 2016-01-26 Isis Pharmaceuticals, Inc. Methods of predicting toxicity
AU2013202595B2 (en) * 2012-03-30 2016-04-21 Biogen Ma Inc. Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013159108A2 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
EP2906255B1 (en) 2012-10-12 2023-02-22 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
EP2912057B1 (en) * 2012-10-24 2018-09-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A microtubuli-modifying compound
US9014359B1 (en) 2013-01-11 2015-04-21 Time Warner Cable Enterprises Llc Generation of phone number lists and call filtering
KR20150130430A (ko) 2013-03-14 2015-11-23 아이시스 파마수티컬즈 인코포레이티드 타우 발현을 조절하는 조성물 및 방법
CN105431153A (zh) * 2013-07-11 2016-03-23 纽约市哥伦比亚大学理事会 使tau表达沉默的微RNA
TWI772856B (zh) * 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
US20170211064A1 (en) 2014-07-29 2017-07-27 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression
JP6350987B2 (ja) 2014-08-04 2018-07-04 本田技研工業株式会社 ＧＨファミリー３に属する耐熱性β―キシロシダーゼ

Also Published As

Publication number Publication date
RU2017127609A (ru) 2019-03-04
IL253730A0 (en) 2017-09-28
US20220143064A1 (en) 2022-05-12
AU2016215155A1 (en) 2017-08-17
JP2018505676A (ja) 2018-03-01
MA41586A (fr) 2017-12-13
EP3653712A1 (en) 2020-05-20
US11077132B2 (en) 2021-08-03
CA2975525A1 (en) 2016-08-11
CO2017009008A2 (es) 2017-11-21
CN107922946A (zh) 2018-04-17
MX2017010066A (es) 2017-11-01
CR20170359A (es) 2017-11-24
CL2017001956A1 (es) 2018-06-01
PE20171766A1 (es) 2017-12-21
US20160237427A1 (en) 2016-08-18
KR20180016970A (ko) 2018-02-20
US20180161356A1 (en) 2018-06-14
EP3253875B1 (en) 2020-01-08
TW201641691A (zh) 2016-12-01
EP3653712B1 (en) 2022-11-30
PH12017550069A1 (en) 2018-02-05
ZA201705119B (en) 2020-01-29
HK1248276A1 (zh) 2018-10-12
WO2016126995A1 (en) 2016-08-11
BR112017016663A2 (pt) 2018-04-10
DK3253875T3 (da) 2020-04-14
US10799523B2 (en) 2020-10-13
SG11201706293XA (en) 2017-09-28
EP3253875A1 (en) 2017-12-13

Similar Documents

Publication Publication Date Title
UY36550A (es) Oligómeros antisentido de tau y sus usos
CL2017000864A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
CL2017001046A1 (es) Inhibidoes del bromodominio
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
TR201808169T3 (tr) Rekombinant probiyotik bakteriler .
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
MX2017000569A (es) Emulsiones de silicona.
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
CL2017001960A1 (es) Métodos de tratamiento de enfermedades inflamatorias
MX391725B (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
MX376201B (es) Compuestos inhibidores de metaloenzima.
MX2017009044A (es) Metodo para el tratamiento de malignidades.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX2017009246A (es) Farmaco de combinacion.
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
MX2017002796A (es) Tasimelteon para tratar el sindrome de smith-magenis.
BR112017025263A2 (pt) método para o tratamento de doença neurológica
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2020005952A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.